EMA Refused: Istodax (romidepsin) — Celgene Europe Ltd.

View source ↗

Summary

The EMA refused approval for Istodax (romidepsin) by Celgene Europe Ltd. for lymphoma/non-Hodgkin indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Istodax (romidepsin)

Snippet

Status: Refused. Therapeutic area: Lymphoma, Non-Hodgkin. MAH: Celgene Europe Ltd.. Decision date: 20/07/2012. Orphan medicine